[Iatrogenic contact eczema].
D000287:Administration, Topical; D000779:Anesthetics, Local / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000935:Antifungal Agents / Q000009:adverse effects; D004396:Coloring Agents / Q000009:adverse effects; D003877:Dermatitis, Contact / Q000453:epidemiology* / Q000517:prevention & control; D003875:Drug Eruptions / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D005859:Germany, East; D006634:Histamine H1 Antagonists / Q000009:adverse effects; D006801:Humans; D007049:Iatrogenic Disease; D008628:Mercury / Q000009:adverse effects; D012494:Sampling Studies; D013449:Sulfonamides / Q000009:adverse effects
D000779:Anesthetics, Local; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D004396:Coloring Agents; D006634:Histamine H1 Antagonists; D013449:Sulfonamides; D008628:Mercury
Beitrag zur Frage iatrogen bedingter Kontaktekzeme.